Analyst Price Targets — RARE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2026 10:30 am | Ben Burnett | Wells Fargo | $50.00 | $26.26 | StreetInsider | Ultragenyx Pharma (RARE) PT Raised to $50 at Wells Fargo |
| August 21, 2026 11:16 am | Maxwell Skor | Morgan Stanley | $74.00 | $25.32 | TheFly | Ultragenyx price target raised to $74 from $67 at Morgan Stanley |
| August 20, 2026 10:54 am | — | Canaccord Genuity | $83.00 | $26.24 | TheFly | Ultragenyx price target raised to $83 from $81 at Canaccord |
| August 20, 2026 10:08 am | — | Wells Fargo | $46.00 | $26.24 | TheFly | Ultragenyx price target raised to $46 from $45 at Wells Fargo |
| August 4, 2026 10:47 am | — | Guggenheim | $35.00 | $25.02 | TheFly | Ultragenyx price target lowered to $35 from $43 at Guggenheim |
| July 13, 2026 12:05 pm | — | Wedbush | $30.00 | $31.94 | TheFly | Ultragenyx price target raised to $30 from $26 at Wedbush |
| July 7, 2026 11:28 am | — | RBC Capital | $40.00 | $33.70 | TheFly | Ultragenyx price target raised to $40 from $35 at RBC Capital |
| May 8, 2026 1:36 pm | — | Wedbush | $26.00 | $26.17 | TheFly | Ultragenyx price target lowered to $26 from $27 at Wedbush |
| May 8, 2026 11:14 am | — | Guggenheim | $43.00 | $26.13 | TheFly | Ultragenyx price target lowered to $43 from $52 at Guggenheim |
| April 29, 2026 9:43 am | Eliana Merle | Barclays | $43.00 | $24.53 | TheFly | Ultragenyx price target lowered to $43 from $44 at Barclays |
Latest News for RARE
Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in aftermarket trading.
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)
At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of at least 50%
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company's common stock to 23 newly hired non-executive officers of the company.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RARE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.